Claret Capital, a European venture debt firm, has raised €575 million to expand its lending to technology and life-sciences companies across the continent, according to a report published September 7, 2026. The fund adds meaningfully to the pool of non-dilutive capital available to European growth-stage companies at a moment when founders and existing investors alike have grown more cautious about the valuation resets and ownership dilution that accompany traditional equity financing rounds in a still-selective fundraising environment.
Venture debt — loans structured specifically for high-growth, often pre-profit companies, frequently alongside warrants or other equity-linked instruments — has become an increasingly prominent tool in European venture financing over the past several funding cycles. For founders, it offers a way to extend runway, fund working capital or bridge to a future equity round without accepting the valuation a private equity or venture round might currently command. For existing shareholders, including venture capital funds under pressure to preserve ownership stakes in portfolio companies, debt financing can be a way to support a company's growth without triggering the dilution that comes with issuing new equity.
Claret's focus spans both technology and life sciences, two sectors with markedly different capital needs — software and platform businesses typically seeking working-capital and growth financing, while life-sciences companies often require capital to bridge clinical or regulatory milestones that can take years to reach revenue-generating maturity. A fund of this size gives Claret meaningful firepower to write larger cheques across both categories at a time when several peer venture debt providers in Europe have also been raising new vehicles, pointing to broader institutional confidence in the asset class even as traditional equity fundraising for growth-stage European startups has remained comparatively subdued through 2026.
The raise underscores a structural shift in how European technology and life-sciences companies are financing growth: rather than treating debt as a last resort, an increasing number of founders are using it as a first-line tool alongside equity, particularly in later funding stages where dilution has the largest absolute impact on founder and early-investor ownership. With €575 million now available for deployment, the coming year will show whether Claret can put that capital to work at the pace and scale the fundraise implies, in a market where competition for high-quality lending opportunities among growth-stage European companies has intensified.
